[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf

1 Section 1860D (i) reads, “NONINTERFERENCE. In order to promote competition underthis part and in carrying out this part, the Secretary (1) may not interfere with the negotiationsbetween drug manufacturers and pharmacies and PDP sponsors; and (2) may not require aparticular formulary or institute a price structure for the reimbursement of covered Part D drugs.”The conference report adds that, “Conferees expect PDPs to negotiate price concessions directlywith manufacturers.” (H.Rept. 108-391, p. 461)Congressional Research Service? ?The Library of CongressCRS Report for CongressReceived through the CRS WebOrder Code RS22059February 18, 2005The Pros and Cons of Allowing the FederalGovernment to Negotiate Prescription Drug PricesJim HahnAnalyst in Social LegislationDomestic Social Policy DivisionSummaryThe Medicare Prescription Drug, Improvement, and Modernization Act (MMA)expressly forbids the Secretary of Health and Human Services (HHS) from negotiatingthe price of prescription drugs on behalf of Medicare beneficiaries. This report outlinesthe arguments for and against allowing the federal government to negotiate prescriptiondrug prices on behalf of Medicare beneficiaries. This repo